{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T21:04:28Z","timestamp":1776373468737,"version":"3.51.2"},"reference-count":55,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,2]],"date-time":"2014-12-02T00:00:00Z","timestamp":1417478400000},"content-version":"vor","delay-in-days":3988,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2004,1]]},"DOI":"10.1111\/j.1469-0691.2004.00752.x","type":"journal-article","created":{"date-parts":[[2004,1,6]],"date-time":"2004-01-06T10:18:19Z","timestamp":1073384299000},"page":"27-36","source":"Crossref","is-referenced-by-count":11,"title":["Clinical and bacteriological efficacy of the ketolide telithromycin against isolates of key respiratory pathogens: a pooled analysis of phase III studies"],"prefix":"10.1016","volume":"10","author":[{"given":"D.E.","family":"Low","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Felmingham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/j.1469-0691.2004.00752.x_bib1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/00019048-199705000-00002","article-title":"IDCP guidelines: management of upper respiratory tract infections","volume":"6","author":"Bartlett","year":"1997","journal-title":"Infect Dis Clin Pract"},{"issue":"suppl 2","key":"10.1111\/j.1469-0691.2004.00752.x_bib2","first-page":"51","article-title":"Upper respiratory tract infections: etiology, current treatment, and experience with fluoroquinolones","volume":"4","author":"Garau","year":"1998","journal-title":"Clin Microbiol Infect"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib3","first-page":"41","article-title":"Acute exacerbations of chronic bronchitis: the clinical problem, patient profiles and recommendations (guidelines) for therapy","volume":"6","author":"Ball","year":"1999","journal-title":"J Infect Dis Antimicrob Agents"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1086\/313954","article-title":"Practice guidelines for the management of community-acquired pneumonia in adults","volume":"31","author":"Bartlett","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib5","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0732-8893(97)00195-8","article-title":"Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in the 1996\u20131997 respiratory season","volume":"29","author":"Thornsberry","year":"1997","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/jac\/45.2.191","article-title":"The Alexander Project 1996\u20131997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections","volume":"45","author":"Felmingham","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib7","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1128\/AAC.39.10.2239","article-title":"Decreased activity of erythromycin against Streptococcus pyogenes in Taiwan","volume":"39","author":"Hsuch","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/jac\/41.1.135","article-title":"Survey of macrolide resistance phenotypes in Swedish clinical isolates of Streptococcus pyogenes","volume":"41","author":"Jasir","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib9","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/jac\/46.6.905","article-title":"In vitro activity of ketolides telithromycin and HMR 3004 against Italian isolates of Streptococcus pyogenes and Streptococcus pneumoniae with different erythromycin susceptibility","volume":"46","author":"Giovanetti","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib10","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa013169","article-title":"Erythromycin-resistant group A streptococci in schoolchildren in Pittsburgh","volume":"346","author":"Martin","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib11","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1097\/00006454-199512000-00016","article-title":"Pneumococcal meningitis during therapy of otitis media with clarithromycin","volume":"14","author":"Reid","year":"1995","journal-title":"Pediatr Infect Dis J"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib12","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1086\/313976","article-title":"Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin","volume":"31","author":"Fogarty","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"suppl 1","key":"10.1111\/j.1469-0691.2004.00752.x_bib13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0924-8579(01)00394-6","article-title":"The clinical impact of macrolide resistance in pneumococcal respiratory infections","volume":"18","author":"Garau","year":"2001","journal-title":"Int J Antimicrob Agents"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib14","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1086\/318157","article-title":"Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin","volume":"31","author":"Kelley","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib15","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2165\/00003495-200161060-00016","article-title":"Telithromycin","volume":"61","author":"Barman Balfour","year":"2001","journal-title":"Drugs"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib16","unstructured":"Agouridas C, Bonnefoy A, Chantot JF. In vitro antibacterial activity of HMR 3647, a novel ketolide highly active against respiratory pathogens [abstract 1.11]. In: Abstracts of the 4th International Conference on the Macrolides, Azalides, Streptogramins and Ketolides, Barcelona, Spain. 1998."},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib17","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1128\/AAC.42.8.2138","article-title":"In vitro activities of the ketolide HMR 3647 against recent Gram-positive clinical isolates and Haemophilus influenzae","volume":"42","author":"Barry","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib18","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1128\/AAC.42.3.624","article-title":"Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents","volume":"42","author":"Pankuch","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib19","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1128\/AAC.42.11.3032","article-title":"Activity of HMR 3647 compared to those of five agents against Haemophilus influenzae and Moraxella catarrhalis by MIC determination and time\u2013kill assay","volume":"42","author":"Pankuch","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib20","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1128\/AAC.42.6.1509","article-title":"In vitro activities of the new ketolide antibiotics HMR 3004 and HMR 3647 against Streptococcus pneumoniae in Germany","volume":"42","author":"Reinert","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib21","series-title":"Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA","first-page":"260","article-title":"In vitro activity of the ketolide HMR 3647 against Streptococcus pyogenes [abstract 1250]","author":"Betriu","year":"1999"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0732-8893(99)00053-X","article-title":"In vitro activity of the novel ketolide HMR 3647 and comparative oral antibiotics against Canadian respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis","volume":"35","author":"Hoban","year":"1999","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib23","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/jac\/44.4.445","article-title":"In-vitro activity of HMR 3647 against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and beta-hemolytic streptococci","volume":"44","author":"Wootton","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib24","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/jac\/45.2.167","article-title":"Macrolide resistance and erythromycin resistance determinants among Belgian Streptococcus pyogenes and Streptococcus pneumoniae isolates","volume":"45","author":"Descheemaeker","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib25","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/jac\/46.6.905","article-title":"In vitro activity of the ketolides telithromycin and HMR 3004 against Italian isolates of Streptococcus pyogenes and Streptococcus pneumoniae with different erythromycin susceptibility","volume":"46","author":"Giovanetti","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib26","unstructured":"Dubois J, St Pierre C. In vitro activity of telithromycin, macrolides and quinolones against respiratory tract pathogens [abstract 2152]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada. Washington, DC: American Society for Microbiology, 2000; 178."},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib27","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1128\/AAC.42.6.1515","article-title":"In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae","volume":"42","author":"Roblin","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib28","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1128\/AAC.42.6.1520","article-title":"Susceptibilities of Legionella spp. to newer antimicrobials in vitro","volume":"42","author":"Sch\u00fclin","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib29","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1128\/AAC.44.7.1980-1982.2000","article-title":"Comparative activities of telithromycin (HMR 3647), levofloxacin and other antimicrobial agents against human mycoplasmas","volume":"44","author":"B\u00e9b\u00e9ar","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib30","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1128\/AAC.44.10.2848-2852.2000","article-title":"In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004 compared to those of clarithromycin against slowly growing mycobacteria at pHs 6.8 and 7.4","volume":"44","author":"Rastogi","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib31","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/00019048-199906000-00003","article-title":"Community-acquired pneumonia due to atypical organisms in adults: diagnosis and treatment","volume":"8","author":"Hammerschlag","year":"1999","journal-title":"Infect Dis Clin Pract"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib32","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1128\/AAC.44.2.414-417.2000","article-title":"In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae","volume":"44","author":"Davies","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 3","key":"10.1111\/j.1469-0691.2004.00752.x_bib33","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1469-0691.2001.00050.x","article-title":"Safeguarding future antimicrobial options: strategies to minimize resistance","volume":"7","author":"Leclercq","year":"2001","journal-title":"Clin Microbiol Infect"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib34","series-title":"Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL","first-page":"461","article-title":"A 5-day course of telithromycin, the first ketolide antimicrobial, is as effective as 10 days' cefuroxime axetil in the treatment of acute maxillary sinusitis [abstract 910]","author":"Buchanan","year":"2001"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib35","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1053\/rmed.2002.1382","article-title":"Telithromycin is as effective as amoxicillin\/clavulanate in acute exacerbations of chronic bronchitis","volume":"96","author":"Aubier","year":"2002","journal-title":"Respir Med"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib36","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1046\/j.1469-0691.2003.00678.x","article-title":"Telithromycin 800 mg once daily for seven to ten days is an effective and well tolerated treatment for community-acquired pneumonia","volume":"9","author":"Carbon","year":"2003","journal-title":"Clin Microbiol Infect"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib37","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s15010-002-2096-z","article-title":"Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia","volume":"30","author":"Hagberg","year":"2002","journal-title":"Infection"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib38","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/00365540110077443","article-title":"Efficacy of short-course therapy with the ketolide telithromycin compared with 10 days' penicillin V in the treatment of pharyngitis\/tonsillitis","volume":"33","author":"Norrby","year":"2001","journal-title":"Scand J Infect Dis"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib39","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000057670","article-title":"Efficacy and tolerability of once-daily therapy with telithromycin for 5 or 10 days for the treatment of acute maxillary sinusitis","volume":"48","author":"Roos","year":"2002","journal-title":"Chemotherapy"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib40","series-title":"Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada","first-page":"471","article-title":"Oral telithromycin (HMR 3647; 800 mg od) is well tolerated and as effective as oral clarithromycin (500 mg bid) in community-acquired pneumonia (CAP) in adults [abstract 2227]","author":"Tellier","year":"2000"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib41","series-title":"Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL","first-page":"449","article-title":"Efficacy and safety of telithromycin 800 mg once daily in pneumococcal community-acquired pneumonia [abstract L-857]","author":"Fogarty","year":"2001"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib42","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0149-2918(03)80087-5","article-title":"Efficacy and tolerability of 5-day, once-daily telithromycin compared with 10-day, twice-daily clarithromycin for the treatment of group A beta-hemolytic streptococcal tonsillitis\/pharyngitis: a multicenter, randomized, double-blind, parallel group study","volume":"25","author":"Quinn","year":"2003","journal-title":"Clin Ther"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib43","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1185\/030079902125001191","article-title":"Efficacy and safety of telithromycin in community-acquired pneumonia","volume":"18","author":"van Rensburg","year":"2002","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib44","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. NCCLS publication no. M7-A4","author":"National Committee for Clinical Laboratory Standards","year":"1997"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib45","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1128\/AAC.40.11.2562","article-title":"Detection of erythromycin-resistant determinants by PCR","volume":"40","author":"Sutcliffe","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 3","key":"10.1111\/j.1469-0691.2004.00752.x_bib46","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1046\/j.1469-0691.2001.00048.x","article-title":"Microbiological profile of telithromycin, the first ketolide antimicrobial","volume":"7","author":"Felmingham","year":"2001","journal-title":"Clin Microbiol Infect"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib47","series-title":"38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA","first-page":"207","article-title":"In vitro bactericidal activity of HMR 3647 against respiratory tract pathogens [Poster E-133]","author":"Felmingham","year":"1998"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib48","series-title":"Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA","first-page":"208","article-title":"In vitro antibacterial activity of HMR 3647, a new ketolide antibiotic [abstract E-137]","author":"Otsuki","year":"1998"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib49","series-title":"Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL","first-page":"36","article-title":"Pharmacokinetics (PK) and pharmacodynamics (PD) of telithromycin in the treatment of community-acquired pneumonia (CAP) [abstract 1388]","author":"Drusano","year":"2001"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib50","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1001\/jama.1996.03530260048030","article-title":"Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis","volume":"275","author":"Fine","year":"1996","journal-title":"JAMA"},{"issue":"suppl 2","key":"10.1111\/j.1469-0691.2004.00752.x_bib51","first-page":"11","article-title":"Predicting antibacterial response from pharmacodynamic and pharmacokinetic profiles","volume":"29","author":"Nicolau","year":"2001","journal-title":"Infection"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib52","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1128\/AAC.45.1.170-175.2001","article-title":"Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses","volume":"45","author":"Namour","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib53","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1001\/archinte.1990.00390200073014","article-title":"The effect of prescribed daily dose frequency on patient medication compliance","volume":"150","author":"Eisen","year":"1990","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib54","first-page":"266","article-title":"Overview of issues related to medical compliance with implications for the outpatient management of infectious diseases","volume":"3","author":"Sclar","year":"1994","journal-title":"Infect Agents Dis"},{"key":"10.1111\/j.1469-0691.2004.00752.x_bib55","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/146642409511500407","article-title":"Compliance with short-term antibiotic therapy among patients attending primary health centres in Riyadh, Saudi Arabia","volume":"115","author":"Al-Shammari","year":"1995","journal-title":"J R Soc Health"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14636909?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14636909?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,28]],"date-time":"2020-03-28T17:17:32Z","timestamp":1585415852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X14636909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["S1198743X14636909"],"URL":"https:\/\/doi.org\/10.1111\/j.1469-0691.2004.00752.x","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2004,1]]}}}